ML-211 was identified as a carbamate-based dual inhibitor of LYPLA1 and the related LYPLA2. ML-211 could inhibit the serine hydrolase ABHD11 (IC50: 10 nM) but was over 50-fold selective for LYPLA in a panel of 20 additional serine hydrolases. Given the high structural homology between LYPLA1 and LYPLA2, it was anticipated that ML211 modified LYPLA2 in an analogous manner. In addition, out of more than 20 serine hydrolases, ML211 was observed to have one anti-target, alpha/beta hydrolase domain-containing protein 11. ML211 and the anti-probe ML226 were evaluated for cell toxicity using both serum-free and serum-supplemented media, and the results showed that both compounds had a CC50 greater than 6 μM, which was 200-fold greater than the concentration necessary for complete inhibition of their respective target enzyme(s) .